Core Viewpoint - The Virtus Terranova U.S. Quality Momentum ETF (JOET) has successfully utilized a quantitative approach to identify high-potential stocks, outperforming the Invesco S&P 500 Equal Weight ETF (RSP) this year [1][2]. Investment Strategy - The ETF's holdings are selected based on a strict rules-based methodology, screening the 500 largest U.S. companies for those with the highest positive momentum over the past 12 months, resulting in a selection of the top 250 stocks [2]. - These selected stocks are then evaluated on three quality factors: return on equity, debt-to-equity ratio, and annualized sales growth rate over the past three years, leading to a final selection of the top 125 stocks for the ETF [3]. Fund Management - Although JOET is not actively managed in a traditional sense, it undergoes quarterly rebalancing, allowing the strategy to capture alpha without emotional biases [4]. - The fund has demonstrated the ability to identify and capitalize on market trends, such as the early investment in Palantir, which has seen significant price appreciation [5][6]. Future Plans - The company plans to expand its suite of ETF products to include other asset classes, such as small-cap and European equities, while maintaining its successful investment strategy [7]. - The JOET fund has an expense ratio of 0.29% and manages approximately $240 million in assets [8].

Core Viewpoint - Kimberly-Clark Corporation's acquisition of Kenvue Inc has raised concerns among shareholders due to Kenvue's ongoing legal issues related to its flagship product, Tylenol [1][3]. Deal Overview - The acquisition is a cash and stock transaction valuing Kenvue at approximately $48.7 billion, with an acquisition multiple of about 14.3 times Kenvue's last twelve months adjusted EBITDA [2]. Legal and Branding Concerns - The primary concern regarding the acquisition is Kenvue's branding and legal challenges, particularly allegations that acetaminophen may increase the risk of autism and attention disorders in children, despite scientific consensus indicating no such link [3][4]. - Texas has filed a lawsuit against Kenvue and Johnson & Johnson for allegedly misleading pregnant women about Tylenol's safety, although the lawsuit has methodological issues regarding correlation and causation [4][5]. Market Analysis - KMB stock has shown a distinct 3-7-D formation in the trailing 10 weeks, indicating three up weeks followed by seven down weeks, with a potential bullish opportunity as price clustering is expected around $107, representing a 3.78% positive delta [12][13]. - A quantitative approach to trading suggests a 105/110 bull call spread as an intriguing trading idea, with a maximum profit potential of over 138% if KMB stock rises above $110 at expiration [17][18].

Core Viewpoint - Kimberly-Clark Corporation's acquisition of Kenvue Inc has raised concerns among shareholders due to Kenvue's ongoing legal issues related to its flagship product, Tylenol [1][3]. Deal Overview - The acquisition is a cash and stock transaction valuing Kenvue at approximately $48.7 billion, with an acquisition multiple of about 14.3 times Kenvue's last twelve months adjusted EBITDA [2]. Legal and Branding Concerns - The primary concern surrounding the acquisition is Kenvue's branding and legal challenges, particularly allegations that acetaminophen, the active ingredient in Tylenol, may increase the risk of autism and attention disorders in children [3]. - Texas has filed a lawsuit against Kenvue and Johnson & Johnson for allegedly misleading pregnant women about the safety of Tylenol, although the lawsuit has methodological issues regarding correlation and causation [4][5]. Market Analysis - KMB stock has shown a distinct 3-7-D formation in the trailing 10 weeks, indicating three up weeks followed by seven down weeks, with a potential bullish opportunity as price clustering is expected around $107, representing a 3.78% positive delta [12][13]. - A quantitative approach to trading suggests a 105/110 bull call spread as an intriguing trading idea, with a maximum profit potential of over 138% if KMB stock rises above $110 at expiration [17][18].

Company Overview - McDonald's (MCD) is recognized as a reliable long-term investment, but its recent performance may not excite options traders [3][4] - MCD stock has increased by 5.48% year-to-date, which is significantly lower than the S&P 500's 15.47% increase [3] Market Sentiment - The Technical Opinion indicator for MCD stock suggests a weak upside potential, with an 8% Buy rating and a Moderate Buy consensus among analysts, including 19 Hold assessments [4] - Options trading activity for MCD has decreased, with total options volume dropping by 29.7% from the previous month, indicating a lack of interest from institutional investors [5] Recent Performance - MCD stock experienced a minimal gain of only 0.18% over the past month, reflecting traders' fatigue with its underwhelming performance [6]